Penicillin Allergy Testing Now Routine: 95% of Labels Are Wrong, New Global Study Confirms

A groundbreaking international study published in April 2026 has transformed how hospitals worldwide approach penicillin allergy testing. The research, involving more than 5,000 patients across 40 hospitals in eight countries, confirms what clinicians have long suspected: approximately 95% of people labeled as allergic to penicillin are not truly allergic.

The Scale of the Problem

Penicillin allergy mislabeling represents one of the most significant yet overlooked challenges in modern healthcare. Roughly 30 million Americans carry a penicillin allergy label in their medical records, yet fewer than 5% have a genuine allergy to this first-line antibiotic class.

The consequences extend far beyond individual patients. Misdiagnosis leads to inappropriate antibiotic prescribing, longer hospital stays, increased healthcare costs, and higher rates of readmissions. Patients with incorrect penicillin allergy labels are more likely to receive broader-spectrum antibiotics associated with serious complications including Clostridioides difficile infections and multi-drug resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus.

The iNAAN Study: A Global Breakthrough

Led by Austin Health in Melbourne, Australia, the International Network of Antibiotic Allergy Nations (iNAAN) study represents the largest investigation into penicillin allergy testing ever conducted. Published in Clinical Infectious Diseases, the research involved hospitals across Australia, the United Kingdom, the United States, Canada, Malaysia, South Africa, Hong Kong, and New Zealand.

Of the 1,573 patients who received a supervised test dose of penicillin as part of the study, 95% were safely confirmed not to be allergic and had their medical records corrected. This correction enables clinicians to prescribe more effective first-line antibiotics and reduce treatment delays.

Professor Jason Trubiano, Chief Principal Investigator at Austin Health, emphasized the significance: "Around 10 per cent of hospitalized patients globally report a penicillin allergy, however most are not truly allergic, often because they were misdiagnosed in childhood, outgrew it or it's been years since their last reaction."

The Smartphone App Innovation

A key breakthrough in the iNAAN study was the implementation of a purpose-built smartphone assessment tool. This clinical decision support system enables doctors, pharmacists, and nurses to identify low-risk patients and safely administer a supervised test dose of penicillin during routine hospital care—even in hospitals without specialist allergy services.

Elise Mitri, Austin Health Drug Allergy Pharmacist and Project Coordinator, explained: "This study shows penicillin allergy testing can be safely integrated into everyday hospital care, ensuring patients receive the most appropriate and effective treatment. The model is already being rolled out in hospitals across Australia and internationally."

Technology-Enabled Delabeling: The Allergy Fact Checker

Parallel research published in npj Digital Medicine in November 2025 demonstrated another innovative approach. Belgian researchers developed the "Allergy Fact Checker," a clinical decision support system that identifies patients with documented uneventful re-exposure to penicillins, enabling delabeling without additional testing.

The study at UZ Leuven hospital found the Allergy Fact Checker identified 8.9% of patients with penicillin allergy labels who had previously received penicillin without reaction. After implementing the system, delabeling rates increased dramatically from 12% to 60%, with an odds ratio of 6.8 (95% CI 1.3–35).

remarkably, addressing each alert required only 5 minutes on average, making this a highly efficient use of clinical resources. The positive predictive value exceeded 90%, ensuring that most recommendations led to successful delabeling.

The Long-Term Care Gap

While hospital-based initiatives gain momentum, long-term care facilities face unique challenges. A Massachusetts statewide survey revealed penicillin allergy prevalence of 23% in long-term care facilities—more than double the rate observed in the general population. More concerning, over 90% of these allergy records were incomplete, lacking information about reaction type or severity.

Residents with documented penicillin allergy were 95% less likely to receive beta-lactam antibiotics for common infections. Those with incomplete documentation were six times more likely to receive high-risk antibiotics for Clostridioides difficile infection, highlighting the urgent need for improved practices in these settings.

Federal Policy Momentum

Recognizing the public health significance of penicillin allergy mislabeling, federal policy attention is building in the United States. The Penicillin Allergy Verification and Evaluation (PAVE) Act (H.R. 5736), reintroduced in October 2025, would include penicillin allergy verification and evaluation as part of the Medicare Initial Preventive Physical Examination and Annual Wellness Visit.

The American Academy of Allergy, Asthma & Immunology and the Infectious Diseases Society of America have expressed strong support for the legislation, noting that improved penicillin allergy evaluation can enhance patient outcomes, reduce healthcare expenditures, and help combat antimicrobial resistance—a critical global health threat.

The Economic and Health Impact

The financial implications of penicillin allergy mislabeling are substantial. Studies consistently demonstrate that patients with incorrect labels incur higher overall costs due to:

• More expensive alternative antibiotics
• Longer hospital stays
• Increased monitoring requirements
• Higher rates of complications from broader-spectrum agents

Beyond costs, the health consequences are serious. Research published in The Lancet and other major journals has linked penicillin allergy labels to increased mortality risk, higher rates of healthcare-associated infections, and reduced access to optimal treatment for serious infections.

Implementation Barriers and Solutions

Despite clear evidence supporting delabeling initiatives, implementation remains fragmented across healthcare systems. Common barriers include:

Workload and Time Constraints: Physicians often overlook delabeling alerts due to competing priorities. The Belgian study found 35% of delayed delabeling cases were attributed to workload issues.

Limited Knowledge: Many clinicians lack familiarity with the allergy label removal process in electronic health record systems. Training programs can empower pharmacists, nurses, and other non-allergist clinicians to safely lead delabeling efforts.

Incomplete Documentation: Without systematic tracking of outcomes such as delabeling rates, adverse events, or cost savings, healthcare systems struggle to demonstrate impact and sustain progress.

The Path Forward

Making penicillin allergy evaluation and delabeling routine will require coordinated efforts across multiple domains:

1. Better Infrastructure: Electronic health records need integrated risk-stratification tools and clinical alerts that help identify low-risk patients at the point of care.

2. Reimbursement Mechanisms: Payment systems should support evaluation and delabeling services in hospitals, outpatient clinics, and long-term care facilities.

3. Workforce Training: Educational programs can prepare non-specialist clinicians to safely conduct delabeling activities using validated protocols.

4. Standardized Outcome Measures: Consistent metrics including delabeling rates, relabeling frequency, adverse reactions, antibiotic spectrum indices, and cost savings are essential to demonstrate impact and ensure accountability.

5. Policy Support: Legislative initiatives like the PAVE Act represent important steps toward federal recognition of this issue, but sustained progress requires inclusion of Medicare populations in long-term care settings.

What Patients Should Know

If you carry a penicillin allergy label, consider discussing delabeling with your healthcare provider, especially if:

• Your original reaction occurred in childhood
• You've received penicillin since without problems
• The documentation is vague or incomplete
• You've needed antibiotics recently and were given alternatives

The iNAAN study participant Nathan, 35, shared his experience: "I have a medical condition that often requires immunosuppressant treatment that makes me more susceptible to respiratory infections. Now that I can have penicillin for flare-ups, I feel more at ease knowing I have access to a potentially lifesaving path of treatment if I need it."

Conclusion

The convergence of large-scale clinical evidence, innovative technology, and growing policy support marks a turning point in addressing penicillin allergy mislabeling. The iNAAN study's demonstration that testing can be safely delivered at scale as part of routine hospital care worldwide represents a paradigm shift from specialist research into global clinical practice.

As Professor Trubiano noted: "Our previous studies showed penicillin allergy testing could be done safely in smaller patient groups and specialist settings. This global study is a game-changer. For the first time, we have shown this approach can be safely implemented at scale across entire hospital systems."

True antimicrobial stewardship means ensuring penicillin allergy evaluation and delabeling are accessible across the care continuum—from academic hospitals to nursing homes. With coordinated investment and inclusive policy frameworks, penicillin allergy evaluation can move from aspiration to standard practice, advancing antibiotic safety and promoting equitable access to high-quality care for all patients.

---

References

1. Mitri E, Trubiano JA, et al; for the International Network of Antibiotic Allergy Nations (iNAAN) study group. Direct oral challenge for penicillin allergy: the International Network of Antibiotic Allergy Nations (iNAAN) study. Clinical Infectious Diseases. 2026 April. https://www.nace.org.au/knowledge-hub/news-media/2026/melbourne-researchers-lead-global-breakthrough-in-penicillin-allergy-testing/

2. Foong KS, MD, FIDSA. Data, policy and practice: What will it take to make penicillin allergy evaluation and delabeling routine? Infectious Diseases Society of America Science Speaks Blog. January 13, 2026. https://www.idsociety.org/science-speaks-blog/2026/data-policy-and-practice-what-it-will-take-to-make-penicillin-allergy-evaluation-and-delabeling-routine/

3. Van De Sijpe G, Gilissen L, Wets D, et al. Evaluation of the Allergy Fact Checker, a clinical decision support system for non-invasive beta-lactam delabeling: a mixed-methods study. npj Digital Medicine. 2025;8:662. DOI: 10.1038/s41746-025-02030-1. https://www.nature.com/articles/s41746-025-02030-1

4. Shenoy ES, Macy E, Rowe T, et al. Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019;321(2):188-199. DOI: 10.1001/jama.2018.19321

5. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10168):183-198. DOI: 10.1016/S0140-6736(18)32218-9

6. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: a cohort study. J Allergy Clin Immunol. 2014;133(4):790-796. DOI: 10.1016/j.jaci.2013.09.021

7. Barlam TF, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77. DOI: 10.1093/cid/ciw118

8. Khan DA, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-1393. DOI: 10.1016/j.jaci.2022.08.009

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making any changes to your medication or treatment plan. Penicillin allergy evaluation should only be performed under appropriate medical supervision.